Rose joins us with an exceptional background and a wealth of experience gained from her time at AstraZeneca and previously in private practice. Her deep understanding of the pharmaceutical sector is a significant asset to our firm and, most importantly, to our clients.
Rose will focus her expertise on several key and rapidly advancing areas including cell and gene therapy, AI drug discovery, and life cycle management strategies for biologics. Her specialist knowledge further strengthen our ability to provide strategic and forward-thinking advice, as we continue to support innovation in the pharmaceutical industry.
We are incredibly excited to welcome Rose to the Evolve Intellectual Property team. Welcome aboard!
